But dramatic selloffs in high-quality businesses have a habit of creating opportunities for investors who can think past the next quarter.<\/p>\n
Here is where each stock stands today.<\/p>\n
![\"Research,](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/10\/health-26-16.9-1200x675.jpeg\")
<\/p>\n
Image source: Getty Images<\/p>\n
CSL<\/p>\n
The fall at CSL has been extraordinary by any measure.<\/p>\n
CSL shares are down approximately 43% in 2026 and more than 60% over the past twelve months, hitting a 10-year low in recent weeks.<\/p>\n
The most recent catalyst was another guidance downgrade.<\/p>\n
Interim CEO Gordon Naylor lowered FY2026 revenue expectations<\/a> to approximately US$15.2 billion on a constant currency basis following a 90-day strategic review.<\/p>\n The market’s patience has run out.<\/p>\n Management has cited weakness in China albumin pricing, inventory normalisation in the US immunoglobulin market, and operational challenges as the primary drivers.<\/p>\n The bull case rests on CSL’s plasma-derived therapies business, which operates behind barriers to entry that no competitor has been able to meaningfully breach in decades.<\/p>\n Plasma collection volumes have recovered from post-COVID lows.<\/p>\n What’s more, the Vifor integration is progressing.<\/p>\n And insiders are now buying shares on market<\/a> for the first time in years, a signal that those closest to the business believe the selloff has gone too far.<\/p>\n The market wants proof of such a sustained recovery, and that means a sustained recovery in sentiment may still take several quarters to materialise.<\/p>\n But at current prices, CSL trades on a valuation it has not seen since before the pandemic.<\/p>\n Cochlear<\/p>\n Cochlear’s 2026 has been even more brutal than CSL’s.<\/p>\n The shares are down 62% year to date<\/a>, touching an eleven-year low in recent weeks.<\/p>\n The April guidance downgrade, which cut FY2026 underlying net profit from $435 to $460 million down to $290 to $330 million, was one of the worst earnings cuts in the company’s listed history.<\/p>\n The causes were a mix of the temporary and the concerning.<\/p>\n Hospital capacity constraints, reduced referral activity, and Middle East disruptions pushed patients to delay surgery.<\/p>\n Cost of living pressures in the US appear to be causing some patients to treat cochlear implants as discretionary rather than essential, at least in the short term.<\/p>\n However, the long-term demand picture has not changed.<\/p>\n